Xcout IntelSign inSubscribe

Daya CNS, LLC

TherapeuticsSaint Louis, MO, United States

Daya CNS is a private biopharmaceutical company headquartered in Saint Peters, Missouri. The company's product pipeline comprises non-opioid treatments and novel antipsychotic drugs designed with fewer side effects.

Subscribe to see Daya CNS, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Daya CNS, LLC at a glance

Daya CNS, LLC is a therapeutics company headquartered in Saint Louis, United States. Its most recent funding round raised $228,310 in August 2015. Xcout tracks 5 named people at Daya CNS, LLC, including Terence Stern (Chief Financial Officer).

As of 16 November 2026. Source: Xcout Intel.

Industry
Therapeutics
Headquarters
Saint Louis, MO, United States

Daya CNS, LLC leadership

  • Terence SternChief Financial Officer
  • Rajagopalan RaghavanChief Scientific Officer
  • Steve HanleyChairman of the Board
  • Jeffrey BooneGeneral Counsel
  • Walter SmithDirector

Daya CNS, LLC funding rounds

Every round on record:

DateRoundAmountInvestors
SEC Form D filing$228,310—

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Daya CNS, LLC competitors

A few of Daya CNS, LLC's closest competitors — see the full list of competitors and alternatives →

Alto Neuroscience, Inc.ANRO · BiotechMountain View, CA, United States
64% matchPublic

Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.

Market cap$1.2B
Employees76
Alto Neuroscience, Inc. competitors & alternatives →

Get Daya CNS, LLC's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Something wrong or missing about Daya CNS, LLC? Suggest a correction · Work at Daya CNS, LLC? Claim this profile

Is this your company? Add the Xcout Intel badge to your website

Free, for any company on Xcout Intel. It links visitors to this profile.

Daya CNS, LLC on Xcout Intel

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Daya CNS, LLC — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Daya CNS, LLC in Xcout Intel

  • 5 named people with titles, LinkedIn and board committees
  • 1 funding round with the investors in each, and who they co-invest with
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →